How about Tian Hong Medical Innovation Fund?

There are more and more new funds listed on the market, and the increase in the number of funds provides investors with a broad choice space. The advantage of the new fund lies in the low subscription rate. Recently, Tian Hong Fund released a new fund, which is Tian Hong Pharmaceutical Innovation Fund. What about this fund?

1 Risk-return characteristics: This fund is a hybrid fund, and its risk-return expectation is higher than that of money market funds and bond funds, but lower than that of equity funds. The Fund will invest in stocks listed in Hong Kong. Under the stock connection mechanism listed in Hong Kong, it will face unique risks brought by differences in investment environment, investment targets, market system and trading rules.

2 Investment strategy: The Fund mainly has a high prestige innovation direction in the pharmaceutical industry in Shanghai and Shenzhen stock markets and Hong Kong stocks. Through in-depth research and bottom-up investment, we choose the direction of high-growth pharmaceutical innovation. The innovation direction of pharmaceutical industry includes innovative drugs (chemical drugs, biological drugs and vaccines), innovative devices and innovative service industry chains (CRO, CDMO). Enterprises involved in the field of innovative medicine include chemical pharmaceutical industry, traditional Chinese medicine industry, biological products industry, pharmaceutical business industry, medical equipment industry, medical service industry and so on.

3 Fund Manager: Mr. Guo: Master's degree from new york University. He used to be the department head of Beijing Tongrentang Technology Development Co., Ltd., joined Tian Hong Fund Management Co., Ltd. in February 20 14, and is now the fund manager of Tian Hong Medicine and Health Hybrid Securities Investment Fund. He used to be the fund manager of Tian Hong Bond Sponsored Securities Investment Fund.